Embracing Change: How Innovators are Advancing Continuous Biopharma Manufacturing

June 12, 2019 8:00 AM - 10:00 AM

MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139

Building on the realization of continuous manufacturing for commercial small molecule APIs and drug products, the dominos finally are beginning to fall into place for the advancement of integrated processes for biopharmaceutical applications. Regulatory engagement, novel and disruptive process and measurement technologies, and simple economics all are playing key roles in recent progress. This forum, intended for a broad audience of scientists and business leaders across the MassBio community, will explore how each of these change-agents are helping to overcome long-time deterrents and, in doing so, have the potential for improving manufacturing reliability and product quality – thereby reducing risks to patients and other key stakeholders.

Discussion and Key Take-Aways Will Include:

  1. Establishing the business case for continuous biomanufacturing – when and for what applications does it make sense?
  2. Applying single-use technologies, automation, and other innovations to enable success in downstream continuous processing.
  3. Advances in measurement and process analytical technologies to enable process/product understanding in alignment with regulatory guidances.
Forum Bonus: We will have extended networking from 10am-11am so you can meet with Bio-Process Systems Alliance, BioPhorum and NIIMBL organizations to learn how they work with industry to accelerate manufacturing innovation as well as find out about their latest white papers, reports and events.
Senior Director Bioprocess Strategy & Development, FUJIFILM Diosynth Biotechnologies
Jonathan has been active in the biopharmaceutical industry for over twelve years working in both the bioprocess technology vendor and end-user sectors. Following a Ph.D. in the Institute of Biotechnology, University of Cambridge (UK), he worked for Pall Corporation (New York, US) developing and evaluating next-generation bioprocessing and analytical technologies to aid Merge and Acquisition (M&A) activities. He subsequently relocated to Fujifilm Diosynth Biotechnologies, a Contract Development and Manufacturing Organisation (CDMO) working within the Process Development function, developing DSP pre-clinical to commercial mammalian and microbial purification processes on behalf of clients through process design, scale-up to GMP manufacture. Prior to his current role, Jonathan was Head of DSP Process Development, leading a team of 60 scientists and engineers, encompassing 10 process development laboratories and three pilot-scale facilities. Jonathan drives a number of internal and external technology and strategy development programmes towards improving protein purification capabilities and GMP operations on behalf of the business. Externally, he sits on the Biophorum Operations Group Technology Roadmap Steering Committee, is an active industrial Ph.D. viva examiner for University College London, Biochemical Engineering Department, acts on the Bioplan Associate's Biotechnology Industry Council Expert Panel, is currently pursing an MBA at the University of Durham Business School, and has a number of patents and publications pertinent to the bioprocessing field.